Loading organizations...
Profluent is an AI-first protein design company, engineering novel, functional proteins using advanced generative models. Its platform integrates deep machine learning with biological experimentation, enabling precise attribute optimization and vast protein sequence exploration. This capability, exemplified by OpenCRISPR, an AI-designed gene editor, drives discovery beyond natural constraints.
Founded in 2022 by Ali Madani, Profluent addresses inefficiencies in traditional protein design. Madani, a former large language model research leader at Salesforce AI Research, pioneered applying generative AI to author complete artificial proteins. His insight focused on AI directly writing new biology, leading to the company's January 2023 launch.
Profluent partners with diverse industries, including medicine, agriculture, and industrial applications, delivering customized AI-driven protein solutions. Its vision is to foster a new biocentury, transforming sectors by providing engineered proteins for critical applications like disease therapies and sustainable enzymes. Profluent aims to solve complex problems via scalable AI.
Profluent Ventures has 1 tracked investment across 1 company. The latest tracked deal is $59.0M Series A in BCB Group in January 2022.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Jan 1, 2022 | BCB Group | $59.0M Series A | Foundation Capital | Bain Capital, Founders Fund, NextView Ventures, Plug & Play Ventures, RET Ventures, Bill Ackman, Marc Baghadjian, Backed, Blockchain.com Ventures, Circle, Cowa Ventures, Digital Currency Group, L1 Digital, LAUNCHub Ventures, Menai Financial Group, Nexo, North Island Ventures, Pantera Capital, Payu, Rockawayx, Benedikt Schulz, Wintermute |